Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ADVM

Adverum Biotechnologies Inc

Mar 27 • 04:00PM ET

4.96

Dollar change -0.08
Percentage change -1.59	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BIIB BMRN CRSP NBIX IONS NTLA SGMO MGTX

| Held by: IWM VTI VXF IWN VTWO IWC DFAT DFAS AVSC VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-6.03	Insider Own	38.24%	Shs Outstand	20.80M	Perf Week	-11.43%
Market Cap	103.18M	Forward P/E	-	EPS next Y	-4.68	Insider Trans	6.35%	Shs Float	12.85M	Perf Month	18.66%
Income	-94.11M	PEG	-	EPS next Q	-1.36	Inst Own	51.11%	Short Float	11.53%	Perf Quarter	4.64%
Sales	1.00M	P/S	103.18	EPS this Y	56.78%	Inst Trans	-10.28%	Short Ratio	8.49	Perf Half Y	-28.53%
Book/sh	6.93	P/B	0.72	EPS next Y	6.71%	ROA	-43.66%	Short Interest	1.48M	Perf Year	-66.82%
Cash/sh	7.37	P/C	0.67	EPS next 5Y	28.94%	ROE	-76.26%	52W Range	3.52 - 15.16	Perf YTD	6.21%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.36%	ROI	-45.53%	52W High	-67.28%	Beta	1.05
Dividend TTM	-	Quick Ratio	5.82	Sales past 5Y	-50.00%	Gross Margin	-285.20%	52W Low	40.91%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	5.82	EPS Y/Y TTM	51.95%	Oper. Margin	-11390.00%	RSI (14)	53.30	Volatility	9.18% 10.55%
Employees	121	Debt/Eq	0.51	Sales Y/Y TTM	-72.22%	Profit Margin	-9411.10%	Recom	1.25	Target Price	29.71
Option/Short	Yes / Yes	LT Debt/Eq	0.43	EPS Q/Q	60.08%	Payout	-	Rel Volume	0.74	Prev Close	5.04
Sales Surprise	700.00%	EPS Surprise	0.54%	Sales Q/Q	-	Earnings	Nov 04 AMC	Avg Volume	174.55K	Price	4.96
SMA20	3.75%	SMA50	10.32%	SMA200	-21.09%	Trades		Volume	130,319	Change	-1.59%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-25-24	Initiated	Oppenheimer	Outperform	$25
Apr-30-24	Initiated	H.C. Wainwright	Buy	$30
Jul-07-22	Upgrade	Truist	Hold → Buy	$4
Jul-23-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-03-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$5
Apr-29-21	Downgrade	Truist	Buy → Hold	$30 → $9
Apr-29-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6
Apr-29-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$5
Dec-16-20	Initiated	UBS	Neutral	$13
Nov-12-20	Upgrade	Raymond James	Underperform → Mkt Perform
Jun-26-20	Downgrade	Raymond James	Mkt Perform → Underperform
May-13-20	Initiated	RBC Capital Mkts	Outperform	$24
May-05-20	Upgrade	SunTrust	Hold → Buy	$13 → $21
Apr-28-20	Initiated	Goldman	Buy	$17
Mar-16-20	Initiated	SVB Leerink	Outperform	$17
Feb-10-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$20
Feb-10-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$8 → $21
Oct-15-19	Reiterated	Chardan Capital Markets	Neutral	$6 → $10
Sep-13-19	Reiterated	Chardan Capital Markets	Neutral	$10 → $6
Jun-14-19	Resumed	Raymond James	Mkt Perform

Show Previous Ratings

Mar-03-25 04:01PM	Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD (GlobeNewswire) -11.68%
Feb-28-25 04:00PM	Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.05%
Feb-25-25 07:00AM	Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference (GlobeNewswire) +9.66%
Feb-05-25 04:05PM	Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-06-24 04:05PM	Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Loading…
Nov-20-24 04:05PM	Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.81%
Nov-18-24 07:00AM	Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements (GlobeNewswire)
Nov-15-24 04:05PM	Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements (GlobeNewswire) -5.38%
Nov-04-24 06:00PM	Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
05:06PM	Adverum Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:39PM	Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones (GlobeNewswire)
Oct-16-24 08:00AM	Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program (GlobeNewswire) +6.76%
Oct-11-24 12:00PM	Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Sep-05-24 07:30AM	Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 04:05PM	Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences (GlobeNewswire)
09:55AM	Loading…
Sep-03-24 09:55AM	Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High? (Zacks)
Aug-12-24 04:35PM	Adverum Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights (GlobeNewswire)
Aug-02-24 07:00AM	Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.55%
Aug-01-24 08:00AM	Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD (GlobeNewswire)
Jul-18-24 09:40AM	Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? (Zacks) +7.97%
Jul-17-24 02:45AM	Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting (GlobeNewswire)
Jul-16-24 09:55AM	Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet (Zacks)
Jul-10-24 08:00AM	Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting (GlobeNewswire)
Jun-18-24 08:00AM	Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit (GlobeNewswire) -9.97%
Jun-11-24 08:00AM	Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilard Kiss as a Member of the Board of Directors (GlobeNewswire)
08:00AM	Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szil rd Kiss as a Member of the Board of Directors (GlobeNewswire)
May-10-24 03:36PM	Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress (GuruFocus.com)
09:35AM	Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) (Zacks)
May-09-24 11:55PM	ADVM Stock Earnings: Adverum Biotechnologies Misses EPS for Q1 2024 (InvestorPlace)
05:45PM	Loading…
05:45PM	Adverum Biotechnologies: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights (GlobeNewswire)
May-03-24 08:00AM	Adverum Biotechnologies to Participate in Upcoming May Investor Conferences (GlobeNewswire)
May-02-24 10:01AM	Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-30-24 07:39AM	HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target (MT Newswires)
Apr-29-24 08:33AM	Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating (MT Newswires)
Apr-25-24 04:05PM	Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting (GlobeNewswire) -7.85%
Apr-23-24 09:40AM	Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? (Zacks)
Apr-19-24 09:35AM	Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) (Zacks)
Apr-04-24 09:40AM	Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? (Zacks)
08:34AM	How Adverum (ADVM) Stock Stands Out in a Strong Industry (Zacks)
Apr-03-24 09:35AM	Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround (Zacks)
Mar-27-24 09:35AM	Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) (Zacks)
Mar-21-24 07:52AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
Mar-20-24 05:33AM	Adverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial Adjustments (GuruFocus.com) -7.88%
Mar-19-24 09:40AM	Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? (Zacks) -6.78%
Mar-18-24 10:53PM	ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023 (InvestorPlace)
04:20PM	Adverum Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates (GlobeNewswire)
Mar-06-24 03:07PM	Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop (InvestorPlace)
Feb-28-24 04:05PM	Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-27-24 06:10AM	Stocks on the Launchpad: The Next 3 Market Sensations (InvestorPlace)
Feb-22-24 06:15AM	Unleash Massive Returns With These 3 Top Penny Stocks (InvestorPlace) +6.60%
Feb-12-24 08:00AM	Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +15.03%
Feb-08-24 07:00AM	Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD (GlobeNewswire) -29.89%
Feb-05-24 07:45AM	Adverum Biotechnologies Announces $127.5 Million Private Placement Financing (GlobeNewswire) +34.51%
Feb-01-24 05:30PM	Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024 (GlobeNewswire) +13.33% +19.33%
Jan-29-24 08:00AM	Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer (GlobeNewswire) +13.89%
Jan-04-24 08:27AM	Here's Why You Should Invest in Adverum (ADVM) Stock Now (Zacks) +6.00%
Dec-07-23 04:05PM	Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society (GlobeNewswire) +9.43% -10.88%
Nov-28-23 04:05PM	Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference (GlobeNewswire)
Nov-09-23 04:51PM	Adverum Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights (GlobeNewswire)
Nov-06-23 08:00AM	Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors (GlobeNewswire)
Nov-04-23 05:54PM	Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Sep-26-23 04:05PM	Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial (GlobeNewswire) +7.50%
Sep-21-23 04:05PM	Adverum Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire) +8.39%
Sep-05-23 04:05PM	Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-21-23 04:05PM	Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer (GlobeNewswire)
Aug-14-23 08:00AM	Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.29%
Aug-10-23 04:20PM	Adverum Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jun-12-23 08:00AM	Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid (GlobeNewswire)
Jun-02-23 08:00AM	Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference (GlobeNewswire) +6.14%
May-25-23 06:30AM	Adverum Biotechnologies Announces New Executive Leadership Roles (GlobeNewswire) +7.41%
May-18-23 09:00AM	Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vecs Phase 2 Clinical Development at ASGCT 2023 Annual Meeting (GlobeNewswire)
09:00AM	Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform (GlobeNewswire)
May-11-23 04:47PM	Adverum Biotechnologies: Q1 Earnings Snapshot (AP Finance)
04:05PM	Adverum Biotechnologies Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-10-23 04:05PM	Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.20%
May-02-23 04:30PM	Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD (GlobeNewswire) -7.42%
Apr-23-23 01:00PM	Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec (GlobeNewswire)
Apr-21-23 06:03AM	After losing 12% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gain (Simply Wall St.) -7.00%
Apr-18-23 08:00AM	Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD (GlobeNewswire)
Apr-17-23 04:05PM	Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting (GlobeNewswire)
Apr-04-23 09:40AM	Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-30-23 04:05PM	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update (GlobeNewswire)
Mar-02-23 10:23AM	Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation (Simply Wall St.)
Feb-27-23 04:05PM	Adverum Biotechnologies to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-18-23 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-06-22 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-10-22 04:05PM	Adverum Biotechnologies Reports Third Quarter 2022 Financial Results (GlobeNewswire) +7.57%
Nov-04-22 12:08PM	Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022) (GlobeNewswire)
Oct-27-22 04:05PM	Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting (GlobeNewswire)
Sep-30-22 04:45PM	Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD (GlobeNewswire) +5.26%
Sep-27-22 04:05PM	Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference (GlobeNewswire) +9.94%
Sep-23-22 04:05PM	Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
11:06AM	Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation (Simply Wall St.)
08:00AM	Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022 (GlobeNewswire)

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leonard Braden Michael	10% Owner	Mar 26 '25	Buy	5.04	20,407	102,841	125,207	Mar 27 07:06 PM
Leonard Braden Michael	10% Owner	Mar 18 '25	Buy	4.69	62,341	292,418	2,667,161	Mar 20 08:02 PM
Leonard Braden Michael	10% Owner	Mar 20 '25	Buy	5.61	30,600	171,767	2,722,761	Mar 20 08:02 PM
Leonard Braden Michael	10% Owner	Mar 19 '25	Buy	4.94	25,000	123,390	2,692,161	Mar 20 08:02 PM
Leonard Braden Michael	10% Owner	Feb 26 '25	Buy	4.01	164,886	660,979	2,432,950	Feb 28 04:04 PM
Leonard Braden Michael	10% Owner	Feb 28 '25	Buy	4.60	85,068	391,015	2,604,820	Feb 28 04:04 PM
Leonard Braden Michael	10% Owner	Feb 27 '25	Buy	4.46	86,802	387,094	2,519,752	Feb 28 04:04 PM
Leonard Braden Michael	10% Owner	Jul 30 '24	Buy	7.15	85,800	613,470	2,268,064	Jul 31 04:19 PM
Leonard Braden Michael	10% Owner	Jul 17 '24	Buy	7.75	135,546	1,049,926	2,101,546	Jul 18 09:16 PM
Leonard Braden Michael	10% Owner	Jul 18 '24	Buy	9.11	80,718	735,736	2,182,264	Jul 18 09:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADVM

Adverum Biotechnologies Inc

Upgrade your FINVIZ experience